Desirudin
FDA-approved recombinant hirudin (Iprivask) — specialty use.
What it's for
Desirudin is recombinant hirudin, a direct thrombin inhibitor from the leech anticoagulant pathway. Indicated for prophylaxis of DVT in patients undergoing elective hip replacement surgery.
What it does for the body
Indicated for prophylaxis of DVT in patients undergoing elective hip replacement surgery. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Irreversible/high-affinity thrombin inhibition prevents fibrinogen cleavage. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Desirudin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Heart research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Desirudin — FDA.gov search
- ClinicalTrials.gov search: Desirudin — U.S. clinical trials registry
- Drugs@FDA search: Desirudin — FDA drug database (if approved)
- PubMed search: Desirudin — NCBI PubMed
- PubMed Central search: Desirudin — NCBI PMC